4-(pyridin-3-yloxy)-1-butanamine | 98607-88-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(pyridin-3-yloxy)-1-butanamine
• 英文别名: 4-(pyridin-3-yloxy)butan-1-amine；4-(3-pyridinyloxy)-1-butanamine；4-(pyridin-3-yloxy)butylamine；4-(3-Pyridinyloxy)butanamine；4-(3-pyridyloxy)-1-butanamine；4-(3-pyridyloxy)butylamine；4-pyridin-3-yloxybutan-1-amine
• CAS: 98607-88-6
• 化学式: C₉H₁₄N₂O
• 分子量: 166.223
• InChiKey: OLIHZSQCXSREQD-UHFFFAOYSA-N

物化性质

• 沸点：
  295.6±20.0 °C(Predicted)
• 密度：
  1.039±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  盐酸小檗碱 、 4-(pyridin-3-yloxy)-1-butanamine 以 乙醇 为溶剂， 以43%的产率得到17-methoxy-N-(4-pyridin-3-yloxybutyl)-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-16-amine;chloride
  参考文献：
  名称：

  Synthesis, biological evaluation of 9-N-substituted berberine derivatives as multi-functional agents of antioxidant, inhibitors of acetylcholinesterase, butyrylcholinesterase and amyloid-β aggregation

  摘要：

  A series of 9-N-substituted berberine derivatives were synthesized and biologically evaluated as antioxidant and inhibitors of acetylcholinesterase (AChE), butyrylcholinesterase and amyloid-beta aggregation. Most of these compounds exhibited very good antioxidant activities, inhibitive activities of AChE and amyloid-beta aggregation. Among them, compound 8d, (o-methylphenethyl)amino linked at the 9-position of berberine, was found to be a good antioxidant (with 4.05 mu M of Trolox equivalents), potent inhibitor of AChE (an IC50 value of 0.027 mu M), and high active inhibitor of amyloid-beta aggregation (an IC50 value of 2.73 mu M). (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.09.051
• 作为产物：
  描述：

  3-羟基吡啶 在 lithium aluminium tetrahydride 、 sodium hydride 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 4.5h， 生成 4-(pyridin-3-yloxy)-1-butanamine
  参考文献：
  名称：

  N-（杂环烷基）吡啶并[2,1-b]喹唑啉-8-羧酰胺为口服活性抗过敏剂。

  摘要：

  评价了一系列N-（杂环烷基）吡啶并[2,1-b]喹唑啉-8-羧酰胺类拮抗豚鼠回肠过敏反应（SRS-A）引起的收缩反应和抑制血栓烷的缓慢反应能力。体外合成酶。结果表明，那些在2-位带有支链烷基部分且在3-或4-取代的吡啶或1之间具有4至6个原子的线性链的吡啶并[2,1-b]喹唑啉-8-甲酰胺在两种测定中，取代的咪唑环和羧酰胺氮原子显示出最佳的效能组合。发现这些化合物中的几种是豚鼠LTE4诱导的支气管收缩和大鼠LTE4诱导的皮肤形成的口服活性抑制剂。最有效的类似物之一，2-（1-甲基-乙基）-N-（1H-咪唑-1-基丁基）-11-氧代-11H-吡啶酮[2，选择1-b]喹唑啉-8-羧酰胺（36）进行广泛的药理研究。已发现该化合物不是LTE4诱导的症状的特异性抑制剂，但通过抑制LTC4，LTD4，PAF诱导的豚鼠支气管痉挛以及LTC4诱导的大鼠和豚鼠中的组胺和皮肤形成而表现出更一般的活性。 ，LT

  DOI：

  10.1021/jm00384a031

文献信息

• Derivatives of (E)-3-(4-oxo-4H-quinazolin-3-yl)-2-propenamide
  申请人：Hoffmann-La Roche Inc.

  公开号：US04599336A1

  公开（公告）日：1986-07-08

  Compounds of the formula ##STR1## wherein R.sub.1 is hydrogen, lower alkyl, lower cycloalkyl, lower alkoxy, hydroxy, halo, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, di-(C.sub.1 -C.sub.7) alkyl-N(CH.sub.2).sub.n O-- or 2-hydroxyethoxy; n is 2 to 7; R.sub.2 is hydrogen, lower alkyl or lower alkoxy; R.sub.3 is hydrogen or methyl; R.sub.4 is hydrogen or lower alkyl; R.sub.5 is hydrogen or lower alkyl provided however if R.sub.2 is other than hydrogen R.sub.5 is hydrogen; m is 1 to 7; Y is ##STR2## --O-- or --S--; w is zero or one; and A is an unsubstituted or substituted aromatic 5- or 6-membered heterocyclic radical; or pharmaceutically acceptable addition salts thereof are described. The compounds of formula I are useful for treating allergic conditions and vascular disorders.

  化合物的公式为##STR1##其中R.sub.1为氢、较低烷基、较低环烷基、较低烷氧基、羟基、卤素、较低烷基硫醚、较低烷基亚砜基、较低烷基砜基、二-(C.sub.1 -C.sub.7)烷基-N(CH.sub.2).sub.n O--或2-羟基乙氧基；n为2至7；R.sub.2为氢、较低烷基或较低烷氧基；R.sub.3为氢或甲基；R.sub.4为氢或较低烷基；R.sub.5为氢或较低烷基，但如果R.sub.2不是氢，则R.sub.5为氢；m为1至7；Y为##STR2##--O--或--S--；w为零或一；A为未取代或取代的芳香5-或6-元杂环基；或其药用接受盐。公式I的化合物可用于治疗过敏症和血管疾病。
• PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE
  申请人：——

  公开号：US20010014691A1

  公开（公告）日：2001-08-16

  Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof aryloxyalkylamines, including pyridyloxylalkylamines and phenoxyalkylamines. Exemplary compounds include dimethyl(2-(3-pyridyloxy)ethylamine, dimethyl(4-(3-pyridyloxy)butyl)amine, 2-(3-pyridyloxy)ethylamine, 4-(3-pyridyloxy)butylamine, methyl(3-(5-methoxy-3-pyridyloxy)propyl)amine, ethyl(3-(3-pyridyloxy)propyl)amine, methyl(2-(3-pyridyloxy)ethyl)amine, methyl(3-(6-methyl(3-pyridyloxy))propyl)amine, (3-(3-methoxyphenoxy)propyl)methylamine, (3-(5-chloro(3-pyridyloxy))-1-methylpropyl)methylamine, dimethyl(3-(3-pyridyloxy)propyl)amine, 3-(3-pyridyloxy)propylamine, methyl(4-(3-pyridyloxy)butyl)amine, 3-(5-chloro-3-pyridyloxy)propyl amine, methyl(3-(5-isopropoxy-3-pyridyloxy)propyl)amine, (3-(5-chloro(3-pyridyloxy))propyl) methylamine, methyl(3-(5-(phenylmethoxy)(3-pyridyloxy))propyl)amine, methyl(3-(2-methyl(3-pyridyloxy))propyl)amine, (methylethyl)(3-(3-pyridyloxy)propyl)amine, benzyl(3-(3-pyridyloxy)propyl)amine, cyclopropyl(3-(3-pyridyloxy)-propyl)amine, methyl(1-methyl-3-(3-pyridyloxy)propyl)amine, methyl(3-(3-nitrophenoxy)propyl)amine, 1-(3-chloropropoxy)-3-nitrobenzene, (3-(3-aminophenoxy)propyl)methylamine,dimethyl (3-(3-(methylamino)-propoxy)phenyl)amine, methyl(3-tricyclo[7.3.1.0<5,13>]tridec-2-yloxypropyl)amine, (3-benzo[3,4-d]1,3-dioxolan-5-yloxypropyl)methylamine, 3-(4-piperidinyloxy)pyridine and 3-((3S)-3-pyrrolidinyloxy)pyridine.

  患有或易受中枢神经系统疾病等病症和紊乱的患者，通过向需要的患者施用芳基氧烷胺类化合物进行治疗，包括吡啶氧烷胺和苯氧烷胺。示例化合物包括二甲基(2-(3-吡啶氧基)乙基)胺，二甲基(4-(3-吡啶氧基)丁基)胺，2-(3-吡啶氧基)乙基胺，4-(3-吡啶氧基)丁基胺，甲基(3-(5-甲氧基-3-吡啶氧基)丙基)胺，乙基(3-(3-吡啶氧基)丙基)胺，甲基(2-(3-吡啶氧基)乙基)胺，甲基(3-(6-甲基(3-吡啶氧基))丙基)胺，(3-(3-甲氧基苯氧基)丙基)甲基胺，(3-(5-氯(3-吡啶氧基))-1-甲基丙基)甲基胺，二甲基(3-(3-吡啶氧基)丙基)胺，3-(3-吡啶氧基)丙基胺，甲基(4-(3-吡啶氧基)丁基)胺，3-(5-氯-3-吡啶氧基)丙基胺，甲基(3-(5-异丙氧基-3-吡啶氧基)丙基)胺，(3-(5-氯(3-吡啶氧基))丙基)甲基胺，甲基(3-(5-(苯甲氧基)(3-吡啶氧基))丙基)胺，甲基(3-(2-甲基(3-吡啶氧基))丙基)胺，(甲基乙基)(3-(3-吡啶氧基)丙基)胺，苄基(3-(3-吡啶氧基)丙基)胺，环丙基(3-(3-吡啶氧基)-丙基)胺，甲基(1-甲基-3-(3-吡啶氧基)丙基)胺，甲基(3-(3-硝基苯氧基)丙基)胺，1-(3-氯丙氧基)-3-硝基苯，(3-(3-氨基苯氧基)丙基)甲基胺，二甲基(3-(3-(甲氨基)-丙氧基)苯基)胺，甲基(3-三环七叁.壹.零<5,13>三十二氧基丙基)胺，(3-苯并三.四-壹,三-二氧杂环戊氧基丙基)甲基胺，3-(4-哌啶氧基)吡啶和3-((3S)-3-吡咯啶氧基)吡啶。
• Pharmaceutical compositions and methods for use
  申请人：Targacept, Inc.

  公开号：US06441006B2

  公开（公告）日：2002-08-27

  Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof aryloxyalkylamines, including pyridyloxylalkylamines and phenoxyalkylamines. Exemplary compounds include dimethyl(2-(3-pyridyloxy)ethylamine, dimethyl(4-(3-pyridyloxy)butyl)amine, 2-(3-pyridyloxy)ethylamine, 4-(3-pyridyloxy)butylamine, methyl(3-(5-methoxy-3-pyridyloxy)propyl)amine, ethyl(3-(3-pyridyloxy)propyl)amine, methyl(2-(3-pyridyloxy)ethyl)amine, methyl(3-(6-methyl(3-pyridyloxy))propyl)amine, (3-(3-methoxyphenoxy)propyl)methylamine, (3-(5-chloro(3-pyridyloxy))-1-methylpropyl)methylamine, dimethyl(3-(3-pyridyloxy)propyl)amine, 3-(3-pyridyloxy)propylamine, methyl(4-(3-pyridyloxy)butyl)amine, 3-(5-chloro-3-pyridyloxy)propylamine, methyl(3-(5-isopropoxy-3-pyridyloxy)propyl)amine, (3-(5-chloro(3-pyridyloxy))propyl)methylamine, methyl(3-(5-(phenylmethoxy)(3-pyridyloxy))propyl)amine, methyl(3-(2-methyl(3-pyridyloxy))propyl)amine, (methylethyl)(3-(3-pyridyloxy)propyl)amine, benzyl(3-(3-pyridyloxy)propyl)amine, cyclopropyl(3-(3-pyridyloxy)-propyl)amine, methyl(1-methyl-3-(3-pyridyloxy)propyl)amine, methyl(3-(3-nitrophenoxy)propyl)amine, 1-(3-chloropropoxy)-3-nitrobenzene, (3-(3-aminophenoxy)propyl)methylamine, dimethyl(3-(3-(methylamino)-propoxy)phenyl)amine, methyl(3-tricyclo[7.3.1.0<5,13>]tridec-2-yloxypropyl)amine, (3-benzo[3,4-d]1,3-dioxolan-5-yloxypropyl)methylamine, 3-(4-piperidinyloxy)pyridine and 3-((3S)-3-pyrrolidinyloxy)pyridine.

  对于容易受到或患有中枢神经系统疾病等疾病和疾病的患者，可以通过给予需要的患者芳基氧烷胺来进行治疗，包括吡啶氧烷胺和苯氧烷胺。示例化合物包括二甲基(2-(3-吡啶氧基)乙基)胺，二甲基(4-(3-吡啶氧基)丁基)胺，2-(3-吡啶氧基)乙基胺，4-(3-吡啶氧基)丁基胺，甲基(3-(5-甲氧基-3-吡啶氧基)丙基)胺，乙基(3-(3-吡啶氧基)丙基)胺，甲基(2-(3-吡啶氧基)乙基)胺，甲基(3-(6-甲基(3-吡啶氧基))丙基)胺，(3-(3-甲氧基苯氧基)丙基)甲基胺，(3-(5-氯(3-吡啶氧基))-1-甲基丙基)甲基胺，二甲基(3-(3-吡啶氧基)丙基)胺，3-(3-吡啶氧基)丙基胺，甲基(4-(3-吡啶氧基)丁基)胺，3-(5-氯-3-吡啶氧基)丙基胺，甲基(3-(5-异丙氧基-3-吡啶氧基)丙基)胺，(3-(5-氯(3-吡啶氧基))丙基)甲基胺，甲基(3-(5-(苯甲氧基)(3-吡啶氧基))丙基)胺，甲基(3-(2-甲基(3-吡啶氧基))丙基)胺，(甲基乙基)(3-(3-吡啶氧基)丙基)胺，苄基(3-(3-吡啶氧基)丙基)胺，环丙基(3-(3-吡啶氧基)-丙基)胺，甲基(1-甲基-3-(3-吡啶氧基)丙基)胺，甲基(3-(3-硝基苯氧基)丙基)胺，1-(3-氯丙氧基)-3-硝基苯，(3-(3-氨基苯氧基)丙基)甲基胺，二甲基(3-(3-(甲基氨基)-丙氧基)苯基)胺，甲基(3-三环[7.3.1.0<5,13>]十三烷-2-氧基丙基)胺，(3-苯并[3,4-d]1,3-二噁烷-5-氧基丙基)甲基胺，3-(4-哌啶氧基)吡啶和3-((3S)-3-吡咯烷氧基)吡啶。
• Derivatives of 4-acetyl-3-hydroxy-2-alkyl-phenoxycarboxylic acids
  申请人：Hoffmann-La Roche Inc.

  公开号：US04672066A1

  公开（公告）日：1987-06-09

  The invention relates to compounds of the formula ##STR1## wherein R is hydrogen or lower alkyl, Y is alkylene; Z is alkylene, ##STR2## the asterisk herein denotes bonding to the substituted acetophenone; R.sub.2 is hydrogen or lower alkoxy; and n is an integer of 1 to 3; A is ##STR3## and HET is a 5-or 6- membered nitrogen containing heterocyclic group, and their acid addition salts. The compounds of formula I of the invention are useful for the treatment of allergic conditions, such as, asthma and cardiovascular diseases, such as, angina and arrhythmias.

  本发明涉及一种公式为##STR1##的化合物，其中R为氢或低级烷基，Y为烷基；Z为烷基，##STR2##此处星号表示与取代的乙酰苯酮结合；R.sub.2为氢或低级烷氧基；n为1至3的整数；A为##STR3##，HET为含有5或6个成员的氮杂环异构基团，以及它们的酸加成盐。本发明的I型化合物可用于治疗过敏症，如哮喘和心血管疾病，如心绞痛和心律失常。
• Pyrido(2,1-b)chinazolinderivate
  申请人：F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft

  公开号：EP0094080A2

  公开（公告）日：1983-11-16

  Es werden Verbindungen der allgemeinen Formel worin eines von D und D' ein Stickstoffatom und das andere ein Kohlenstoffatom, die gestrichelte Linie zwei zusätzliche Bindungen, R1 und R2 unabhängig von einander Wasserstoff, niederes Alkyl, niederes Alkoxy, Hydroxy oder Halogen, X -0-oder -N(R5)-, R5 Wasserstoff oder niederes Alkyl, R3 (C2-7)-Alkylen, R4(C1-7)-Alkylen Y -0- oder -S-, m 0 oder 1, n 0 oder 1 und A eine unsubstituierte oder substituierte aromatische, 5-oder 6-gliedrige heterocyclische Gruppe bedeuten, mit der Massgabe, daß m und n beide 0 sind, wenn A über ein heterocyclisches Stickstoffatom gebunden ist, beschrieben. Diese Verbindungen und ihre pharmazeutisch annehmbaren Säureadditionssalze sind nützlich als Mittel für die Behandlung von Allergien und thrombotischen Gefässerkrankungen.

  通式如下的化合物 其中 D 和 D'之一为氮原子，另一个为碳原子，虚线为两个附加键，R1 和 R2 独立地为氢、低级烷基、低级烷氧基、羟基或卤素，X 为-0-或-N(R5)-，R5 为氢或低级烷基、R3为(C2-7)-烯烃，R4为(C1-7)-烯烃，Y为-0-或-S-，m为0或1，n为0或1，A为未取代或取代的芳香族、5或6元杂环基团，但当A通过杂环氮原子连接时，m和n均为0。这些化合物及其药学上可接受的酸加成盐可作为治疗过敏症和血栓性血管疾病的药物。